Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
&NA; Psychedelics comprise drugs come from various pharmacological classes including 5‐HT2A agonists, indirect 5‐HT agonists, e.g., MDMA, NMDA antagonists and &kgr;‐opioid receptor agonists. There is resurgence in developing psychedelics to treat psychiatric disorders with high unmet clinical need. Many, but not all, psychedelics are schedule 1 controlled drugs (CDs), i.e., no approved medical use. For existing psychedelics in development, regulatory approval will require a move from schedule 1 to a CD schedule for drugs with medical use, i.e., schedules 2–5. Although abuse of the psychedelics is well documented, a systematic preclinical and clinical evaluation of the risks they pose in a medical‐use setting does not exist. We describe the non‐clinical tests required for a regulatory evaluation of abuse/dependence risks, i.e., drug‐discrimination, intravenous self‐administration and physical dependence liability. A synopsis of the existing data for the various types of psychedelics is provided and we describe our findings with psychedelic drugs in these models. FDA recently issued its guidance on abuse/dependence evaluation of drug‐candidates (CDER/FDA, 2017). We critically review the guidance, discuss the impact this document will have on non‐clinical abuse/dependence testing, and offer advice on how non‐clinical abuse/dependence experiments can be designed to meet not only the expectations of FDA, but also other regulatory agencies. Finally, we offer views on how these non‐clinical tests can be refined to provide more meaningful information to aid the assessment of the risks posed by CNS drug‐candidates for abuse and physical dependence. This article is part of the Special Issue entitled ‘Psychedelics: New Doors, Altered Perceptions’. HighlightsVarious psychedelics are undergoing clinical evaluation as treatments for psychiatric disorders.The non‐clinical abuse and/or dependence testing of psychedelic drugs is reviewed.Self‐administration, drug‐discrimination and dependence methods are discussed.Experimental data for psychedelics in abuse/dependence models are critically reviewed.Refinements to abuse/dependence testing models are proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Policy: NIH to balance sex in cell and animal studies
Clayton, J. A., & Collins, F. S. (2014) · Nature · doi:10.1038/509282a · Cited by 1,816 · cited 1×
“Certainly that is the view of the National Institute for Health (NIH) which has recently recommended that drugs for human use be pharmacologically evaluated in both males and females in animal experiments (Clayton and Collins, 2014; Clayton, 2016).”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“Ketamine's utility in treating disorders including treatment-resistant depression (DiazGranados et al., 2010; Murrough et al., 2013; Singh et al., 2016), PTSD (Feder et al.”
BackgroundGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“In addition, it has been shown that it is not possible to produce head-twitches in mice lacking the 5-HT2A receptor (Gonz alez-Maeso et al., 2007).”
BackgroundFeder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · cited 1×
“Ketamine's utility in treating disorders including treatment-resistant depression (DiazGranados et al., 2010; Murrough et al., 2013; Singh et al., 2016), PTSD (Feder et al.”
BackgroundSingh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · cited 1×
“Ketamine's utility in treating disorders including treatment-resistant depression (DiazGranados et al., 2010; Murrough et al., 2013; Singh et al., 2016), PTSD (Feder et al., 2014) and alcohol dependence (Krupitsky and Grinenko, 1997) is also under investigation.”
BackgroundStudying both sexes: a guiding principle for biomedicine
Clayton, J. A. (2016) · The FASEB Journal · doi:10.1096/fj.15-279554 · Cited by 358
Good Laboratory Practice: Preventing Introduction of Bias at the Bench
Macleod, M. R., Fisher, M., O'Collins, V., Sena, E. S., Dirnagl, U., Bath, P. M. W., Buchan, A., van der Worp, H. B., Traystman, R., Minematsu, K., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.525386 · Cited by 331
Self‐administration of drugs in animals and humans as a model and an investigative tool
Panlilio, L. V., & Goldberg, S. R. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.02011.x · Cited by 322 · cited 2×
“…reader's attention to other reviews on the general methodological aspects of IVSA testing (Johanson, 1990; Balster, 1991; Ator and Griffiths, 2003; Panlilio and Goldberg, 2007), IVSA testing in rats (O'Connor et al., 2011) and primates (Howell and Fantegrossi, 2009), and also reviews proposing…”
BackgroundEnadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
Walsh, S., Strain, E., Abreu, M., & Bigelow, G. (2001) · Psychopharmacology · doi:10.1007/s002130100788 · Cited by 258 · cited 2×
“Enadoline was compared with butorphanol and hydromorphone in drug-experienced volunteers (Walsh et al., 2001a) and its influence on the pharmacodynamics and selfadministration of cocaine have been investigated (Walsh et al., 2001b).”
BackgroundMethod
Cited by
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Psychedelics, Sociality, and Human Evolution
Rodríguez Arce, J. M., & Winkelman, M. J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.729425 · Cited by 86
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
Metadata
- Authors
- Heal, D. J., Gosden, J., & Smith, S. L.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 142
- Pages
- 89-115
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2790698047
- Cited by
- 49
- References
- 18
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.01.049
- The paper
- Heal, D. J., Gosden, J., & Smith, S. L. (2018). Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.01.049
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.